Navigation Links
Study finds glioblastoma patients treated with bevacizumab experience reduced cognitive function and quality of life
Date:5/31/2013

CHICAGO, IL Many glioblastoma patients treated with bevacizumab (Avastin) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.

The findings from the large national multi-center Phase III trial, RTOG 0825, were presented today at the annual meeting of the American Society of Clinical Oncology.

Glioblastoma is the most frequent and aggressive type of brain tumor. Despite slight gains, tumors pose a high risk of recurrence and are commonly fatal.

Previous studies found bevacizumab, a monoclonal antibody directed against the vascular endothelial growth factor, prolongs progression-free survival (PFS) in patients with recurrent glioblastoma.

RTOG 0825, one of the largest trials to study the clinical benefit of a brain tumor treatment, evaluated newly diagnosed patients treated with bevacizumab, in addition to standard chemoradiation and maintenance temozolomide, versus those who received a placebo and standard treatment.

Tests measured effects of treatment

Using objective tests of cognitive function and subjective measures of symptoms and quality of life, 507 patients were evaluated at diagnosis and at intervals throughout treatment as long as scans showed their tumors were not progressing.

"Most studies rely on traditional endpoints, including overall survival and radiographic outcomes, such as PFS, with little attention to the impact of the disease and therapies on the patient," said Jeffrey Wefel, Ph.D., associate professor in MD Anderson's Department of Neuro-Oncology and a senior author on the study. "This makes the potential clinical benefit difficult to ascertain."

Neurocognitive changes

At the beginning of the study, patients' neurocognitive function in both groups was below healthy population norms. Longitudinal analyses showed those treated with bevacizumab compared to ones treated with placebo demonstrated greater decline in global neurocognitive function, executive function (skills involved in tasks such as planning, organizing and multi-tasking) and processing speed.

Additionally, baseline performance and early change (through week 10) in global neurocognitive function, memory, executive function and processing speed were prognostic for survival.

"Relatively little attention has been directed toward investigating patient biomarkers associated with outcomes," Wefel said. "We sought to determine if patient cognitive function was a biomarker associated with progression-free and overall survival (OS) time. We found patients with worse cognitive function at baseline, and those who experienced cognitive decline after concurrent chemoradiation with or without bevacizumab, were at greater risk for shorter PFS and OS time."

Quality of life and side effects

Symptoms and quality of life were significantly worse for patients receiving bevacizumab, particularly at weeks 22 and 34. In particular, symptom burden, including treatments, and generalized and affective symptoms were greater, with persistent differences seen in treatment-associated symptoms. Additionally, overall symptom burden, tumor and treatment-related symptoms, as well symptoms that interfered with daily activities, were also worse for those on bevacizumab over the treatment course.

Baseline and early change rating of both symptoms and quality of life, like neurocognitive function, were also prognostic for survival.

"The idea of our research was to put together the total picture of this treatment, not only how it affects the tumor, but how it affects patients and how they go about their lives," said Terri Armstrong, Ph.D., adjunct professor in MD Anderson's Department of Neuro-Oncology. "It was our hope this treatment would improve life for them, but that just wasn't the case. For many, both tumor and treatment-related symptoms were worse and continued to get worse over time."

Next steps

"We're eager to continue investigating the data within this trial to identify subsets of patients for whom a particular therapeutic approach may have been associated with a favorable net clinical benefit for survival, cognition, symptoms and quality of life," Wefel said.


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... Greifensee, Switzerland (PRWEB) , ... May 31, 2016 , ... ... adopt this model in their laboratories as well. However, laboratories have different challenges compared ... many benefits of lean operations in the lab, METTLER TOLEDO has developed the ...
(Date:5/31/2016)... , ... May 31, 2016 , ... ... and numeral energies can describe personality traits in humans. Using presidential candidate Donald ... their name and vitality. , “AstroNumerology is not about adding numbers up,” ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... Phynd Technologies, ... Vidalia, GA; Houston Methodist – Houston, TX and Shore Medical Center – Somers Point, ... use three different, leading EHR solutions, demonstrating the breadth of Phynd’s solution and its ...
(Date:5/31/2016)... ... , ... Dr. Charles A. Ditta attained his Doctor of Medical Dentistry Degree ... 1986, where he graduated in the top ten percentile of his class. Dr. Ditta ... He has been a member in good standing for thirty years in the American ...
(Date:5/31/2016)... ... , ... Super Powder, a supplement produced by Prox Formulas for providing ... continues to transform the nutritional supplement industry by providing a safe, natural approach to ... acids (BCAA), alkaline minerals, wheat grass, digestive enzymes, Omega 3’s, Vit D3, Vit A, ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... According to a new market ... by Type (Human, Animal Pathology), by End User (Pharmaceutical ... - Global Forecasts to 2021", published by MarketsandMarkets, studies ... of 2016 to 2021. This market is expected to ... Million in 2016, at a CAGR of 12.1%. ...
(Date:5/31/2016)... May 31, 2016 Aloe vera ... food, cosmetics and pharmaceuticals, with global volume to surpass ... 1.6 Bn. Demand for aloe vera extracts ... yogurts will continue its upward momentum in 2016 as ... boost positive sentiment on aloe vera, with wide-ranging applications ...
(Date:5/31/2016)... , May 31, 2016 ... World Health Assembly zur Eliminierung von viraler Hepatitis ... Mitgliedsstaaten eine historische Verpflichtung eingegangen, virale Hepatitis bis ... . World Health Assembly haben sich die ... bzgl. viraler Hepatitis (Global Viral Hepatitis Strategy) zu ...
Breaking Medicine Technology: